https://orcid.org/0000-0001-5696-4894
References
- National Hemophilia Foundation. Fast Facts. About Bleeding Disorders. 2020. Available at https://www.hemophilia.org/About-Us/Fast-Facts. [Accessed May 4, 2020].
- World Federation of Hemophilia. Mild Hemophilia (Revised November 2012). 2020. Available at: http://www1.wfh.org/publication/files/pdf-1192.pdf. [Accessed September 24, 2020].
- Centers for Disease Control and Prevention. Hemophilia. Treatment of Hemophilia. 2020. Available at https://www.cdc.gov/ncbddd/hemophilia/treatment.html. [Accessed May 4, 2020].
- Tiede A. Half-life extended factor VIII for the treatment of hemophilia A. J Thromb Haemost. 2015;13(Suppl 1):S176–S9.
- Witmer C, Young G. Factor VIII inhibitors in hemophilia A: rationale and latest evidence. Ther Adv Hematol. 2013;4(1):59–72.
- Dalton DR. Hemophilia in the managed care. Am J Manag Care. 2015;21(suppl 6):S123–S130.
- Brown TM, Lee WC, Joshi AV, et al. Health-related quality of life and productivity impact in haemophilia patients with inhibitors. Haemophilia. 2009;15(4):911–917.
- Zhou Z-Y, Koerper MA, Johnson KA, et al. Burden of illness: direct and indirect costs among persons with hemophilia a in the United States. J Med Econ. 2015;18(6):457–465.
- Chambers JD, Wilkinson CL, Anderson JE, et al. Variation in private payer coverage of rheumatoid arthritis drugs. J Manag Care Spec Pharm. 2016;22(10):1176–1181.
- Chambers JD, Anderson JE, Wilkinson CL, et al. Variation in the coverage of disease-modifying multiple sclerosis drugs among US payers. Am J Pharm Benefits. 2017;9(5):155–159.
- National Hemophilia Foundation. MASAC recommendations concerning products licensed for the treatment of hemophilia and other bleeding disorders (Revised February 2020). 2020. Available at: https://www.hemophilia.org/sites/default/files/document/files/259_treatment.pdf. [Accessed May 8, 2020].
- Chambers JD, Kim DD, Pope EF, et al. Specialty drug coverage varies across commercial health plans in the US. Health Aff. 2018;37(7):1041–1047.
- National Association of Insurance Commissioners. Accident and health policy experience report. 2019. 2018. Available at: https://www.naic.org/prod_serv/AHP-LR-19.pdf. [Accessed August 24, 2020].
- Chambers JD, Panzer AD, Kim DD, et al. Variation in US private health plans' coverage of orphan drugs. Am J Manag Care. 2019;25(10):508–551.
- Knobe K, Berntorp E. Haemophilia and joint disease: pathophysiology, evaluation, and management. J Comorb. 2011;1:51–59.
- Food and Drug Administration. FDA approves emicizumab-kxwh for hemophilia A with or without factor VIII inhibitors. 2020. Available at: https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-emicizumab-kxwh-hemophilia-or-without-factor-viii-inhibitors. [Accessed May 8, 2020].
- Chambers JD. Large health gains, but challenges for health care payers. What can we expect from gene therapies? In: 12th annual conference of the israeli society for pharmacoeconomics and outcomes research. Herzliya; 2019.